Abstract
To investigate the effect of an HMG-CoA reductase inhibitor, CS-514, on the serum levels of lipid, lipoprotein including Lp (a) and apoprotein, CS-514, in a dosage of 10mg a day, was administered for 12 weeks to 15 patients with hypercholesterolemia of which 5 patients had heterozygous familiar hypercholesterolemia. Before and after 4, 8 and 12 weeks of treatment, blood was collected after 12 hours of fasting. Serum total cholesterol and triglyceride levels were determined by enzymatic methods. HDL cholesterol level was determined by the heparin-Ca method. Apoprotein A-I, A-II, B, C-II, C-III, E and Lp (a) lipoprotein levels were measured by single radial immunodiffusion (SRID) methods. The total cholesterol level significantly decreased from 311±61 to 267±57mg/dl, whereas the HDL cholesterol level significantly increased from 52.1±16.1 to 59.2±20.3mg/dl. Both triglyceride and Lp (a) levels remained virtually unchanged (from 164±131 to 150±115mg/dl, from 23.0±17.2 to 23.6±18.3mg/dl, respectively). The serum levels of apo A-I and A-II significantly increased whereas that of apo B significantly decreased. No significant changes were found in the serum levels of either apo C-II, C-III, or E. No significant untoward reactions were observed.
